ESHG 2025: Recap & Highlights
We’re pleased to share a brief recap of our successful participation in ESHG 2025, which took place this May in Milan. With nearly 7,000 total registrations from over 94 countries, the European Hum..
News Room Latest Articles
Initial results from the DART study indicate that Medicover Genetics’ MRD test can detect minimal residual disease in lung cancer patients
02 June 2025 – Medicover announces positive interim results from the DART clinical study conducted by Oslo University Hospital. The interim results indicate that by using Medicover Genetics’ minima..
Medicover Genetics integrates Element Biosciences’ AVITI™ sequencing system into VERACITY™ NIPT workflow and IVDR-certified genomic kits
23 May 2025 – Medicover Genetics, a leading innovator in genetic diagnostics and laboratory enablement, today announced the successful integration of Element Biosciences’ AVITI™ sequencing system..
Medicover Genetics’ MRD technology featured in NSCLC study presented at ASCO 2025
23 May 2025 – Medicover Genetics is proud to announce that its proprietary circulating tumor DNA-based minimal residual disease (MRD) assay has been utilized in a clinical study selected for presenta..
Medicover Genetics Publishes First Report of Tissue-Specific Genetic Analysis and Genotype–Phenotype Correlation in Child with Mosaic Trisomy 18
Medicover Genetics is pleased to announce the publication of a letter to the editor in the Journal of Perinatal Medicine co-authored by several members of the Medicover Genetics team. The letter docu..
Successful participation at Medlab Middle East 2025: Driving innovation in genetic diagnostics
We are pleased to share the highlights of our successful participation in Medlab Middle East 2025, held from February 3-6, 2025, at the Dubai World Trade Centre. As the region’s premier laboratory ..
Medicover Genetics publishes insights on advances in non-invasive prenatal testing
Medicover Genetics is pleased to announce the publication of an article by PD Markus Stumm in Scientia highlighting advances in screening for genetic abnormalities with non-invasive prenatal testing ..
EDITORIAL TEAM
Our editors are a diverse group of scientists and physicians specialized in different areas of genetics and genetic testing technologies. Owing to our various backgrounds, our editors represent a broad range of expertise and are responsible for the content shared on our website. Only evidence-based, peer-reviewed, and up-to-date content is shared, and all text is continuously edited to maximize its correctness.
